WO2011066285A3 - Peptide-based treatment for neurodegenerative diseases - Google Patents

Peptide-based treatment for neurodegenerative diseases Download PDF

Info

Publication number
WO2011066285A3
WO2011066285A3 PCT/US2010/057809 US2010057809W WO2011066285A3 WO 2011066285 A3 WO2011066285 A3 WO 2011066285A3 US 2010057809 W US2010057809 W US 2010057809W WO 2011066285 A3 WO2011066285 A3 WO 2011066285A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
methods
neurodegenerative diseases
disclosed
based treatment
Prior art date
Application number
PCT/US2010/057809
Other languages
French (fr)
Other versions
WO2011066285A2 (en
Inventor
Daniel Desire Tshala-Katumbay
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Publication of WO2011066285A2 publication Critical patent/WO2011066285A2/en
Publication of WO2011066285A3 publication Critical patent/WO2011066285A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

Disclosed herein are peptide conjugates and methods for use of such for treating subjects with an axonal disorder. In an example, a conjugate includes a tetanus toxin peptide (Tet-1) with the amino acid sequence set forth by SEQ ID NO: 1 (HLNILSTLWKYR), an optional spacer moiety, an optional one or more amino acids, a tetrapeptide including at least two cysteine or two lysine residues. Methods of reducing or inhibiting one or more symptoms associated with an axonal disorder by administering a therapeutically effective amount of a pharmaceutical composition including a disclosed conjugate are also provided.
PCT/US2010/057809 2009-11-24 2010-11-23 Peptide-based treatment for neurodegenerative diseases WO2011066285A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26407609P 2009-11-24 2009-11-24
US61/264,076 2009-11-24

Publications (2)

Publication Number Publication Date
WO2011066285A2 WO2011066285A2 (en) 2011-06-03
WO2011066285A3 true WO2011066285A3 (en) 2011-11-03

Family

ID=44067197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/057809 WO2011066285A2 (en) 2009-11-24 2010-11-23 Peptide-based treatment for neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2011066285A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064457A1 (en) * 2002-01-29 2003-08-07 Antisense Pharma Gmbh A method for inhibiting 'melanoma inhibitory activity' mia
US20040248188A1 (en) * 2000-06-28 2004-12-09 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
WO2006105392A2 (en) * 2005-03-30 2006-10-05 The Cleveland Clinic Foundation Neuron targeting peptides
US20060275327A1 (en) * 2003-09-16 2006-12-07 Sylvie Roux In vivo modulation of neuronal transport

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248188A1 (en) * 2000-06-28 2004-12-09 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
WO2003064457A1 (en) * 2002-01-29 2003-08-07 Antisense Pharma Gmbh A method for inhibiting 'melanoma inhibitory activity' mia
US20060275327A1 (en) * 2003-09-16 2006-12-07 Sylvie Roux In vivo modulation of neuronal transport
WO2006105392A2 (en) * 2005-03-30 2006-10-05 The Cleveland Clinic Foundation Neuron targeting peptides

Also Published As

Publication number Publication date
WO2011066285A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
He et al. The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012142320A8 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
UA107571C2 (en) PHARMACEUTICAL COMPOSITION
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
JP2012176978A5 (en)
EP2455462A3 (en) Lipase variants for pharmaceutical use
EP2532365A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
JP2012501973A5 (en)
WO2011157713A3 (en) Cell-penetrating peptides and uses therof
NZ602824A (en) Sparc binding peptides and uses thereof
UA95996C2 (en) Pegylated fab antibody fragment that specifically binds human a-beta peptide
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
NZ593926A (en) Methods and compositions based on shiga toxin type 2 protein
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
RU2010144014A (en) APPLICATION OF PEGILIATED IGF-I OPTIONS FOR TREATMENT OF NEUROMUSCULAR DISORDERS
MX2022003268A (en) Selective drug release from internalized conjugates of biologically active compounds.
US11433028B2 (en) Compositions for treating viral infections and methods for same
WO2011059263A3 (en) Peptide which passes through blood-brain barrier and targets apoptosis of neurodegenerative brain disease site and uses thereof
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
KR20140014068A (en) Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
JP2004533250A5 (en)
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10833858

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10833858

Country of ref document: EP

Kind code of ref document: A2